Eosinophilic fasciitis (EF) and morphea are rare sclerosing connective tissue disorders, and there remains debate about whether these entities are pathologically distinct or related. This case report describes the successful treatment of an adolescent patient who developed progressive morphea plaques while being treated with systemic corticosteroids, intravenous immunoglobulin, and methotrexate for EF. A novel combination of topical tofacitinib, a Janus kinase (JAK) inhibitor, and UVA-1 phototherapy induced clinical remission and was well tolerated, warranting further investigation into such combination therapy.
Cheung et al. (Mon,) studied this question.